163 related articles for article (PubMed ID: 37042716)
1. Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
Cantini L; Paoloni F; Pecci F; Spagnolo F; Genova C; Tanda ET; Aerts S; Rebuzzi SE; Fornarini G; Zoratto F; Fancelli S; Lupi A; Della Corte CM; Parisi A; Bennati C; Ortega C; Atzori F; Piovano PL; Orciuolo C; De Tursi M; Ghidini M; Botticelli A; Scagnoli S; Belluomini L; Leporati R; Veccia A; Di Giacomo AM; Festino L; Cortinovis D; Acquati M; Filetti M; Giusti R; Tucci M; Sergi MC; Garutti M; Puglisi F; Manglaviti S; Citarella F; Santoni M; Rijavec E; Lo Russo G; Santini D; Addeo A; Antonuzzo L; Indini A; Rocchi MBL; Cortellini A; Grossi F; Ascierto PA; Aerts JGJV; Berardi R
J Natl Cancer Inst; 2023 Jul; 115(7):796-804. PubMed ID: 37042716
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study.
Colard-Thomas J; Manceron C; Duflos C; Herman F; Simon M; Maria ATJ; Faillie JL; Viala M; Palassin P
ESMO Open; 2023 Dec; 8(6):102070. PubMed ID: 37988951
[TBL] [Abstract][Full Text] [Related]
3. A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan.
Ito T; Kaku-Ito Y; Ohno F; Nakahara T
Front Med (Lausanne); 2023; 10():1293397. PubMed ID: 38143437
[TBL] [Abstract][Full Text] [Related]
4. A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors.
Morimoto K; Yamada T; Morimoto Y; Ishikawa T; Asai J; Fujihara A; Arai A; Katoh N; Ukimura O; Hirano S; Itoh Y; Takayama K
Int Immunopharmacol; 2022 Jul; 108():108775. PubMed ID: 35436741
[TBL] [Abstract][Full Text] [Related]
5. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
6. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
Nigro O; Pinotti G; De Galitiis F; Di Pietro FR; Giusti R; Filetti M; Bersanelli M; Lazzarin A; Bordi P; Catino A; Pizzutilo P; Galetta D; Marchetti P; Botticelli A; Scagnoli S; Russano M; Santini D; Torniai M; Berardi R; Ricciuti B; De Giglio A; Chiari R; Russo A; Adamo V; Tudini M; Silva RR; Bolzacchini E; Giordano M; Di Marino P; De Tursi M; Rijavec E; Ghidini M; Vallini I; Stucci LS; Tucci M; Pala L; Conforti F; Queirolo P; Tanda E; Spagnolo F; Cecchi F; Bracarda S; Macrini S; Santoni M; Battelli N; Fargnoli MC; Porzio G; Tuzi A; Suter MB; Ficorella C; Cortellini A
Eur J Cancer; 2020 Jul; 134():19-28. PubMed ID: 32454395
[TBL] [Abstract][Full Text] [Related]
7. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
8. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
McQuade JL; Hammers H; Furberg H; Engert A; André T; Blumenschein G; Tannir N; Baron A; Larkin J; El-Khoueiry A; Carbone DP; Thomas JM; Hennicken D; Coffey M; Motzer RJ
JAMA Oncol; 2023 Jan; 9(1):102-111. PubMed ID: 36480191
[TBL] [Abstract][Full Text] [Related]
9. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
10. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
Li L; Li G; Rao B; Dong AH; Liang W; Zhu JX; Qin MP; Huang WW; Lu JM; Li ZF; Wu YZ
Sci Rep; 2020 Sep; 10(1):15567. PubMed ID: 32968172
[TBL] [Abstract][Full Text] [Related]
11. [Incidence of Immune-Related Adverse Events after Switching from a Conventional Regimen of Nivolumab and Pembrolizumab to the Extended Dosing Interval Regimen].
Taga S; Asano H; Iwai M; Takenaka S; Moriya A; Otsuka T; Kimura M; Yoshimura T
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1093-1097. PubMed ID: 36281601
[TBL] [Abstract][Full Text] [Related]
12. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
13. Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer.
Truong J; Yeung SST; Kletas V; de Lemos M; Schaff K; Nakashima L
J Oncol Pharm Pract; 2023 Sep; ():10781552231199048. PubMed ID: 37654194
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.
Ando T; Ueda A; Ogawa K; Motoo I; Kajiura S; Nakajima T; Hirano K; Okumura T; Tsukada K; Hara T; Suzuki N; Nakada N; Horikawa N; Fujii T; Yasuda I
In Vivo; 2021; 35(1):475-482. PubMed ID: 33402499
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
16. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
17. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.
Wang W; Gu X; Wang L; Pu X; Feng H; Xu C; Lou G; Shao L; Xu Y; Wang Q; Wang S; Gao W; Zhang Y; Song Z
Cancer Immunol Immunother; 2022 Jul; 71(7):1693-1703. PubMed ID: 34817639
[TBL] [Abstract][Full Text] [Related]
19. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Naqash AR; Ricciuti B; Owen DH; Florou V; Toi Y; Cherry C; Hafiz M; De Giglio A; Muzaffar M; Patel SH; Sugawara S; Burkart J; Park W; Chiari R; Sugisaka J; Otterson GA; de Lima Lopes G; Walker PR
Cancer Immunol Immunother; 2020 Jul; 69(7):1177-1187. PubMed ID: 32140762
[TBL] [Abstract][Full Text] [Related]
20. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
Miura K; Sano Y; Niho S; Kawasumi K; Mochizuki N; Yoh K; Matsumoto S; Zenke Y; Ikeda T; Nosaki K; Kirita K; Udagawa H; Goto K; Kawasaki T; Hanada K
Thorac Cancer; 2021 Jul; 12(13):1983-1994. PubMed ID: 33990133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
